Skip to main content

SkinFactory 2.0: GMP-in-a-box

Project description

Promising 'skins' created from a patient's own skin cells are moving through clinical trials

The primary function of the skin is protection from mechanical impact, temperature changes, microorganisms, chemicals and radiation. Millions of people worldwide suffer from severe skin damage and removing that critical barrier exposes them to dangerous pathogens. Surgical interventions such as skin grafts are often painful and plagued by scarring. Further, multiple surgeries may be necessary to address the damage. SkinFactory 2.0 has developed the technology to produce novel, bioengineered skin grafts from a patient's own cells. The grafts are currently in phase II clinical trials in Europe. EU funding is supporting the application of cutting-edge 'Good Manufacturing Practices (GMP)-in-a-box' technology for en masse production of autologous cell therapies, overcoming current methods limited to small quantities under the strictest GMP guidelines.

Call for proposal

H2020-INNOSUP-2019-02
See other projects for this call

Coordinator

CUTISS AG
Address
Weinbergstrasse 35 Wyss Translational Center Zurich Denovos
8006 Zurich
Switzerland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 183 125